FDA approves Roche drug for late-stage breast cancer

WASHINGTON, Feb 25: US health regulators approved a new drug made by Swiss drugmaker Roche Holding AG for some patients with late-stage metastatic breast cancer who fail to respond to other therapies. The US Food and Drug Administration said on Friday it had approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose cancer cells contain increased amounts of a protein known as HER2. (agencies)

LEAVE A REPLY

Please enter your comment!
Please enter your name here